New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating

By Noor Ul Ain Rehman | September 30, 2025, 4:00 AM

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target.

Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?

The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling investors in a research note that Apogee Therapeutics Inc.’s (NASDAQ:APGE) early clinical and more recent Phase II atopic dermatitis data exhibited the beneficial properties of APG777 and its combo therapies.

RBC sees considerable revenue opportunities across several inflammation and immunology indications, supporting the optimistic rating.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications.

While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News

5 hours
Oct-10
Oct-09
Oct-09
Oct-08
Oct-08
Sep-30
Sep-15
Sep-11
Sep-03
Aug-11
Aug-06
Jul-31
Jul-16
Jul-14